Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9800-0.1200 (-5.71%)
As of 11:55AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 7.02M
Enterprise value -1.43M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.74
Price/book (mrq)0.98
Enterprise value/revenue -0.66
Enterprise value/EBITDA 0.19

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-86.11%
S&P500 52-week change 3-14.73%
52-week high 317.4000
52-week low 31.6600
50-day moving average 32.5435
200-day moving average 34.4902

Share statistics

Avg vol (3-month) 333.5k
Avg vol (10-day) 317.06k
Shares outstanding 53.34M
Implied shares outstanding 6N/A
Float 82.35M
% held by insiders 12.46%
% held by institutions 12.11%
Shares short (14 Sept 2022) 435.77k
Short ratio (14 Sept 2022) 41.91
Short % of float (14 Sept 2022) 41.10%
Short % of shares outstanding (14 Sept 2022) 41.07%
Shares short (prior month 14 Aug 2022) 459.79k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 322 May 2022

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-348.01%

Management effectiveness

Return on assets (ttm)-29.55%
Return on equity (ttm)-122.36%

Income statement

Revenue (ttm)2.17M
Revenue per share (ttm)0.77
Quarterly revenue growth (yoy)95.20%
Gross profit (ttm)1.29M
EBITDA N/A
Net income avi to common (ttm)-8.05M
Diluted EPS (ttm)-2.9850
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.45M
Total cash per share (mrq)4.02
Total debt (mrq)5M
Total debt/equity (mrq)69.53
Current ratio (mrq)10.65
Book value per share (mrq)2.15

Cash flow statement

Operating cash flow (ttm)-10.88M
Levered free cash flow (ttm)-8.36M